🔥🐔 BizChicken 🐔🔥

Companies Similar to bluebird bio, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Mustang Bio, Inc.

Mustang Bio, Inc. logo
Market Cap: Lowest
Employees: Low

Gene and CAR T Cell Therapies

Mustang Bio, Inc. is a biopharmaceutical company specializing in cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. It focuses on developing gene therapy programs and CAR T cell therapies, including treatments for X-linked severe combined immunodeficiency and various types of cancer.

Tags: CAR T cell, biopharmaceutical, gene therapy, genetic diseases, hematologic cancers, solid tumors

Symbol: MBIO

Recent Price: $0.19

Industry: Biotechnology

CEO: Dr. Manuel Litchman M.D.

Sector: Healthcare

Employees: 80

Address: 377 Plantation Street, Worcester, MA 01605

Phone: 781 652 4500

Leadership

  • Manuel Litchman, M.D., President, Chief Executive Officer and Director
  • Greg Furrow, M.S., FRQA, Chief Quality Officer
  • James Murphy, B.A., Ad interim Chief Financial Officer
  • Michael S. Weiss, Chairman of the Board of Directors
  • Lindsay A. Rosenwald, M.D., Director
  • Adam J. Chill, Director
  • Neil Herskowitz, Director
  • Michael J. Zelefsky, M.D., Director
  • Mustang Bio, Inc., Company

Last updated: 2024-12-31

Adicet Bio, Inc.

Adicet Bio, Inc. logo
Market Cap: Low
Employees: Low

ADI-001

Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Their lead product ADI-001 is in Phase I clinical study for non-Hodgkin's lymphoma, with additional products in development for solid tumors.

Tags: allogeneic treatments, biotechnology, cancer therapy, gamma delta T cell, immunotherapy

Symbol: ACET

Recent Price: $0.90

Industry: Biotechnology

CEO: Mr. Chen Schor BA, CPA, M.B.A.

Sector: Healthcare

Employees: 143

Address: 200 Clarendon Street, Boston, MA 02116

Phone: 650 503 9095

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

BioVie Inc.

BioVie Inc. logo
Market Cap: Lowest
Employees: Lowest

BIV201, NE3107

Bio Vie Inc., a clinical stage biotechnology company, focuses on discovering, developing, and commercializing drug therapies in the United States, with products targeting liver cirrhosis, Alzheimer's, Parkinson's, multiple myeloma, and prostate cancer.

Tags: Alzheimer's, Biotechnology, Clinical Trials, Drug Development, Liver Cirrhosis, Parkinson's, Pharmaceutical

Symbol: BIVI

Recent Price: $2.09

Industry: Biotechnology

CEO: Mr. Cuong Viet Do M.B.A.

Sector: Healthcare

Employees: 14

Address: 680 West Nye Lane, Carson City, NV 89703

Phone: 775 888 3162

Last updated: 2024-12-31

Belite Bio, Inc

Belite Bio, Inc logo
Market Cap: High
Employees: Lowest

LBS-008

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics for age-related macular degeneration and Stargardt diseases. Its lead product candidate, LBS-008, is in phase 3 clinical trials.

Tags: Stargardt diseases, biopharmaceutical, clinical-stage, drug development, liver disease, macular degeneration, phase 3, therapeutics

Symbol: BLTE

Recent Price: $61.97

Industry: Biotechnology

CEO: Dr. Yu-Hsin Lin M.B.A., Ph.D.

Sector: Healthcare

Employees: 20

Address: 5820 Oberlin Drive, San Diego, CA 92121

Phone: 858-246-6240

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Benitec Biopharma Inc.

Benitec Biopharma Inc. logo
Market Cap: Low
Employees: Lowest

BB-301 and BB-103

Benitec Biopharma Inc. is a development-stage biotechnology company specializing in DNA-directed RNA interference-based therapeutics for chronic and life-threatening conditions. Its lead products include BB-301 for oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection.

Tags: RNA interference, biotechnology, chronic conditions, gene therapy, genetic medicines, hepatitis B, oculopharyngeal muscular dystrophy

Symbol: BNTC

Recent Price: $12.51

Industry: Biotechnology

CEO: Dr. Jerel A. Banks M.D., Ph.D.

Sector: Healthcare

Employees: 16

Address: 3940 Trust Way, Hayward, CA 94545

Phone: 510 780 0819

Leadership

  • Jerel Banks, M.D., Ph.D., Chief Executive Officer & Chairman of the Board
  • Megan Boston, Executive Director

Last updated: 2024-12-31

Blueprint Medicines Corporation

Blueprint Medicines Corporation logo
Market Cap: Highest
Employees: Medium

AYVAKIT, BLU-263, Fisogatinib, GAVRETO, BLU-701, BLU-945, BLU-451, BLU-782

Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, including treatment for systemic mastocytosis, gastrointestinal stromal tumors, hepatocellular carcinoma, and non-small-cell lung carcinoma.

Tags: AYVAKIT, BLU-263, Fisogatinib, GAVRETO, blood disorders, epidermal growth factor receptor, genomically defined cancers, non-small cell lung cancer, precision therapy, solid tumors

Symbol: BPMC

Recent Price: $86.82

Industry: Biotechnology

CEO: Ms. Kathryn Haviland M.B.A.

Sector: Healthcare

Employees: 638

Address: 45 Sidney Street, Cambridge, MA 02139

Phone: 617 374 7580

Last updated: 2024-12-31

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

CGT9486

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.

Tags: biotechnology, genetically defined diseases, precision therapies, tyrosine kinase inhibitor

Symbol: COGT

Recent Price: $7.67

Industry: Biotechnology

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Employees: 164

Address: 200 Cambridge Park Drive, Cambridge, MA 02140

Phone: 617 945 5576

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

Instil Bio, Inc.

Instil Bio, Inc. logo
Market Cap: Low
Employees: Lowest

ITIL-168, ITIL-306

Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.

Tags: TIL, biopharmaceutical, cancer therapy, cell therapy, clinical-stage

Symbol: TIL

Recent Price: $18.99

Industry: Biotechnology

CEO: Mr. Bronson Crouch

Sector: Healthcare

Employees: 49

Address: 3963 Maple Avenue, Dallas, TX 75219

Phone: 972 499 3350

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

XBiotech Inc.

XBiotech Inc. logo
Market Cap: Low
Employees: Low

True Human monoclonal antibodies

XBiotech Inc. discovers, develops, and commercializes True Human monoclonal antibodies targeting inflammatory and infectious diseases, with additional development in interleukin-1 alpha therapies for various medical conditions and COVID-19 therapy.

Tags: COVID-19, antibodies, biopharmaceutical, cancer, diseases, inflammation, therapies

Symbol: XBIT

Recent Price: $4.09

Industry: Biotechnology

CEO: Mr. John Simard

Sector: Healthcare

Employees: 94

Address: 5217 Winnebago Lane, Austin, TX 78744

Phone: 512 386 2900

Last updated: 2024-12-31

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. logo
Market Cap: Medium
Employees: Medium

platform for cell programming

Ginkgo Bioworks Holdings, Inc. develops a platform used to program cells for biological production of products such as therapeutics, food ingredients, and chemicals. It serves markets in specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Tags: agriculture, biotechnology, cell programming, food ingredients, novel therapeutics, pharmaceuticals, specialty chemicals

Symbol: DNA

Recent Price: $9.44

Industry: Biotechnology

CEO: Dr. Jason Kelly

Sector: Healthcare

Employees: 1218

Address: 27 Drydock Avenue, Boston, MA 02210

Phone: 877 422 5362

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. logo
Market Cap: High
Employees: Medium

AG10, BBP-265, BBP-831, BBP-631, Encaleret

Bridge Bio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases, with a pipeline of 30 programs including candidates like AG10, BBP-265, and others in various stages of clinical trials.

Tags: biopharmaceuticals, clinical trials, drug development, genetic diseases

Symbol: BBIO

Recent Price: $27.32

Industry: Biotechnology

CEO: Dr. Neil Kumar Ph.D.

Sector: Healthcare

Employees: 550

Address: 421 Kipling Street, Palo Alto, CA 94301

Phone: 650 391 9740

Last updated: 2024-12-31

IN8bio, Inc.

IN8bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

INB-200, INB-100, INB-400, INB-300

IN8bio, Inc. is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer treatment, with lead products in clinical trials and preclinical development.

Tags: biopharmaceutical, biotechnology, cancer treatment, clinical trials, gamma-delta T cell therapies

Symbol: INAB

Recent Price: $0.27

Industry: Biotechnology

CEO: Mr. Tai-Wei Ho

Sector: Healthcare

Employees: 39

Address: 350 5th Avenue, New York, NY 10118

Phone: 646 600 6438

Last updated: 2024-12-31

Nektar Therapeutics

Nektar Therapeutics logo
Market Cap: Low
Employees: Low

Bempegaldesleukin

Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs. Their products include Bempegaldesleukin, an IL-2 pathway agonist in clinical trials for various cancers and COVID-19, and NKTR-358, a cytokine Treg stimulant for autoimmune diseases.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, medicines, oncology

Symbol: NKTR

Recent Price: $0.94

Industry: Biotechnology

CEO: Mr. Howard W. Robin

Sector: Healthcare

Employees: 137

Address: 455 Mission Bay Boulevard South, San Francisco, CA 94158

Phone: 415 482 5300

Leadership

  • Howard W. Robin, President & Chief Executive Officer
  • Robert Bacci, Senior Vice President, HR and Facilities Operations
  • Sandra Gardiner, Chief Financial Officer
  • Jennifer Ruddock, Chief Business Officer
  • Mary Tagliaferri, M.D., Chief Medical Officer
  • Mark A. Wilson, Chief Legal Officer
  • Jonathan Zalevsky, Ph.D., Chief Research & Development Officer

Last updated: 2024-12-31